Assessing efficacy of therapeutic intervention on myocardial infarction process by enzymatic prediction method

Efficacy of drug therapy in reduction of enzymatically estimated infarction size, was often assessed by enzymatic prediction method. But the drawback of this method is that, this can assess neither the utility of early administration of drug therapy nor the clinical effects of the drug. Predicted infarction size (PIS) does not include reinfarctions. Therefore, in such studies cases of reinfarctions are either to be excluded or PIS should be compared with modified infarction size (MIS). Moreover, a large number of patients (not a few ones) should be included in trial for correct assessment of the utility of therapy.